Further studies should focus on the beneficial effect of the compounds that target APJ and explain the therapeutic effect of novel synthetic ligands for APJ receptor in diabetes and obesity. The gene discussed is APLNR; the disease is obesity due to melanocortin 4 receptor deficiency.